The graduate students in the Department of Pharmacology named their annual forum the Joel G. Hardman Student-Invited Pharmacology Forum, in recognition of Dr. Hardman's sustained interest in the training of young scientists.
Joel G. Hardman served as Chair of the Department of Pharmacology from 1975-1990, establishing the department as a premier place for research and training in pharmacology. A major reason for the success of the Training Program in Pharmacological Sciences was Dr. Hardman's personal involvement in the mentoring of each graduate student. He expected each student to perform at their best and created an intellectual environment that fostered the scientific growth and critical thought of students, postdoctoral fellows and faculty colleagues.
Joel G. Hardman received his Ph.D. degree in Pharmacology from Emory University in 1964. He came to Vanderbilt to be a postdoctoral fellow with Earl Sutherland. After his early work on cyclic AMP as a second messenger, carried out in Sutherland's laboratory, Dr. Hardman went on to discover guanylate cyclase, the enzyme responsible for synthesizing cyclic GMP from GTP. This discovery led to the appreciation that cGMP, like cAMP, can serve as an intracellular second messenger. He rose through the ranks to become Professor of Physiology in 1972. His creative and incisive mind, which contributed to his discoveries, also served him well in his role as teacher and mentor. In 1975, he was appointed as Chair of Pharmacology, and in 1991 was named Associate Vice-Chancellor for Health Affairs.
Dr. Hardman is internationally recognized as an outstanding scientist, educator and administrator. In 1992, Dr. Hardman became Co-Editor-In-Chief of the major text in Pharmacology, Goodman and Gilman's The Pharmacological Basis of Therapeutics, which is published in many languages worldwide. He served as President of the American Society for Pharmacology and Experimental Therapeutics in 1993/1994.
2013 Student Forum Schedule:ABOUT THE SPEAKERS:
University of Wisconsin-Madison
Dr. Koenigs received his B.S. from the University of Wisconsin-Madison in 2002 and his Ph.D. degree in 2006 from the University of Iowa. He completed his postdoctoral fellowship at the National Institutes of Health (NINDS) from 2006-2008. Dr. Koenigs joined the faculty at the University of Wisconsin-Madison in 2008.
Research Interests of the Koenigs Lab: The goal of Dr. Koenigs’s research is to identify and characterize the brain circuits underlying emotion and social behavior. To this end, they primarily study two clinical populations with notable deficits in these domains: first, they study neurological and neurosurgical patients who have undergone dramatic changes in emotion, personality, and social behavior as a result of focal brain lesions. Second, they study prison inmates with psychopathy, a mental health disorder characterized by impulsive antisocial behavior and a marked lack of empathy and guilt. In 2009, Dr. Koenigs was awarded an NIMH Mentored Research Scientist Development Award.
David Goldman, M.D.,Senior Investigator,Laboratory of Neurogenetics,National Institute on Alcohol Abuse and Alcoholism (NIAAA),National Institutes of Health, Rockville, MD
Dr. Goldman received his B.S. from Yale University in 1974. He received his M.D. degree in 1978 and completed residency training in psychiatry in 1979, both at the University of Texas Medical Branch. Dr. Goldman joined the NIAAA in 1979 and has been Chief of the Laboratory of Neurogenetics since 1991.
Research Interests of the Goldman Lab: Throughout his career, Dr. Goldman has focused on the identification of genetic factors responsible for inherited differences in behavior. His laboratory is currently exploring the genetics of alcoholism and related psychiatric diseases, and is well-known for his work identifying effects of functional genetic variants on intermediate phenotypes for complex behavioral diseases. Awards that Dr. Goldman has received include NIMH Director’s Honor Award for genetic factors that my alter susceptibility to schizophrenia, James Isaacson Research Award, International Society for Biological Research on Alcoholism, and the NIH Director’s Award for the years 2002 and 2010. Dr. Goldman is author of, “Our Genes, Our Choices.”
Dr. Alia-Klein received her B.A. from Adelphi University in 1998. She received her M.S. and M.Phil. degrees in 2000 and 2001, respectively, from Columbia University. In January 2013, Dr. Alia-Klein became Professor and Co-Chief of Neuroimaging of Addictions and Related Conditions in the Department of Psychiatry, with a Secondary Appointment in the Departmenf of Neuroscience/Friedman Brain Institute at Mount Sinai School of Medicine in New York.
Research Interests of the Alia-Klein Lab: Dr. Alia-Klein’s research centers on gene-brain-behavior modeling to predict anger and reactive aggression in clinical diagnoses as Intermittent Explosive Disorder for which she has an R01. She studies the neurochemistry modulating these behaviors and the reactivity interplay of prefrontal and subcortical brain regions during provocation or other challenge. Her tools probe select genotypes and their effects on brain function through application of MRI and PET technology. Her clinical background helps her hone on characterizing the phenotype and is further enriched by her expertise in neuroimaging in the past decade. She is a NY state licensed clinical psychologist.